R
Reinsurance Group of America, Incorporated
RGA · Financial Services
Q4 FY2025
Earning ended Dec 31, 2025Report generated Mar 10, 2026
Five Decades of Mortality Data Build a Moat the Market Ignores
The market prices RGA as a commodity financial company exposed to pandemic volatility, but the real story is that its proprietary biometric dataset — accumulated across hundreds of millions of life-years and dozens of global populations — becomes more valuable, not less, as AI-powered underwriting separates disciplined pricers from sloppy ones. The asset-intensive reinsurance wave, driven by PE-backed insurers offloading investment risk from bloated annuity books, is a structural growth engine that looks nothing like the traditional mortality risk transfer business this company is usually benchmarked against.
Flowly Score
Apr 16 Close
+5%$208.73
Fair Value
$220.00
71
Strongat $208.73
Business Strength7/10
A genuine actuarial oligopoly with switching costs that operate like gravity — once a cedant's book is entangled in a decades-long treaty, departure is functionally impossible. The proprietary mortality dataset is irreplaceable, but ROIC languishing across five years signals that moat durability isn't translating into expanding economics on new business, capping the score.
Financial Resilience7/10
The float engine makes this one of the cleanest cash-conversion stories in financial services — reported earnings are a conservative floor, not a ceiling, because premiums are collected before claims are paid. Near-zero capital expenditure means virtually all operating cash flow is genuinely free, though the massive reserve portfolio introduces interest-rate sensitivity that can cut the other way in a prolonged low-rate environment.
Growth & Trajectory7/10
The secular asset-intensive reinsurance wave — driven by private equity-backed insurers desperate to shed investment risk from swollen annuity books — is a structural tailwind the market hasn't fully underwritten, and Asia-Pacific premium growth from an expanding middle class provides genuine long-runway optionality. The drag is that reinsurance growth is capital-consumptive by nature, so the compounding math never fully escapes the need to feed the beast.
Valuation7/10at $206.38
Trading at a compressed earnings multiple on record results, with EV-to-EBITDA also well below what a business with these switching costs and data barriers deserves — the market appears to be applying a generic financial-company discount to what is functionally a toll road on global mortality risk. The standard DCF scenarios are analytically meaningless for a life reinsurer, but on honest earnings and book-value anchors, this looks like a business priced for decline that is actually positioned for a structurally improving decade.
Risk6/10
The most plausible slow-burn threat isn't another pandemic — it's GLP-1 drugs and wearable health data reshaping mortality curves faster than a decades-old actuarial framework can reprice, potentially turning long-dated liabilities into structural surprises. Secondary to that, private equity-backed Bermuda reinsurers with a lower cost of capital and appetite for volume are already commoditizing simpler mortality risk, and that pricing pressure is beginning to migrate up the complexity curve toward RGA's home turf.
RGA sits at the intersection of two powerful structural shifts — the demand for sophisticated mortality risk transfer in emerging Asian insurance markets, and the swelling need for asset-intensive reinsurance from an insurance industry being reshaped by private equity capital. Against those tailwinds, the market has quietly compressed the earnings multiple to a level that implies no growth and no moat, which is empirically wrong on both counts. You're being offered durable switching costs, a cornered actuarial dataset, and a business generating genuine cash flow at a price that would be appropriate for a shrinking, commoditized risk-taker. The quality-price interaction here is genuinely attractive. Where this business is heading is more interesting than where it's been. The exit from US group health — shedding a low-margin, high-volatility line after imposing aggressive repricing — signals management willing to prune rather than empire-build. Capital is being redirected toward asset-intensive transactions like the Equitable block, which blend biometric and investment risk in exactly the way RGA's combined skill set is most differentiated. With roughly five billion deployed since 2023 still ramping through earnings trajectories, the earnings power embedded in the current book is structurally larger than trailing numbers suggest. The single biggest risk is actuarial obsolescence from structural biological shifts. GLP-1 drugs are already meaningfully improving cardiovascular and metabolic outcomes across large populations — if that extends meaningfully to all-cause mortality over a decade, RGA's longevity reinsurance and pension risk transfer liabilities, priced on older mortality tables, become ticking reserve adjustments. This isn't a pandemic scenario where claims spike and then normalize; it's a slow-moving degradation of the pricing assumptions baked into long-dated contracts that can't be repriced mid-treaty. That specific risk deserves far more analytical attention than the market currently applies to it.